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O fracionamento biomonitorado do extrato diclorometânico das sementes de Pterodon 
pubescens Benth forneceu o 6α-acetóxi-7β-hidróxi-vouacapano 1 (inédito), além de quatro 
diterpenos furânicos (2, 3, 4 e 5). A atividade antiproliferativa dos compostos foi avaliada in 
vitro contra as linhagens de células tumorais humanas UACC-62 (melanoma), MCF-7 (mama), 
NCI-H460 (pulmão), OVCAR-03 (ovário), PC-3 (próstata), HT-29 (colon), 786-0 (rim), K562 
(leucemia) e NCI-ADR/RES (ovário com fenótipo de resistência a múltiplos fármacos). Os 
resultados foram expressos em três concentrações efetivas GI
50
 (concentração para que ocorra 50% 
de inibição de crescimento), TGI (concentração que resulta em inibição total de crescimento) e 
LC
50 
(concentração que resulta em 50% de morte celular). A citotoxicidade in vitro foi avaliada 
também frente a uma linhagem de célula murina normal (3T3). Este é o primeiro relato de atividade 
anticâncer para os compostos 1, 4 e 5, que apresentaram grande seletividade, dependente da 
concentração, para PC-3. O composto 1 foi 26 vezes mais potente para inibir 50% do crescimento 
(GI
50
) de PC-3, 15 vezes mais citostático (TGI) e 6 vezes menos tóxico (LC
50
) quando comparado 
com Doxorrubicina (controle).
Activity guided fractionation of Pterodon pubescens Benth. methylene chloride-soluble 
fraction afforded novel 6α-acetoxi 7β-hydroxy-vouacapan 1 and four known diterpene furans  
2, 3, 4, 5. The compounds were evaluated for in vitro cytotoxic activities against human normal 
cells and tumour cell lines UACC-62 (melanoma), MCF-7 (breast), NCI-H460 (lung, non-small 
cells), OVCAR-03 (ovarian), PC-3 (prostate), HT-29 (colon), 786-0 (renal), K562 (leukemia) and 
NCI-ADR/RES (ovarian expressing phenotype multiple drugs resistance). Results were expressed 
by three concentration dependent parameters GI
50
 (concentration that produces 50% growth 
inhibition), TGI (concentration that produces total growth inhibition or cytostatic effect) and LC
50
 
(concentration that produces −50% growth, a cytotoxicity parameter). Also, in vitro cytotoxicity 
was evaluated against 3T3 cell line (mouse embryonic fibroblasts). Antiproliferative properties of 
compounds 1, 4 and 5 are herein reported for the first time. These compounds showed selectivity 
in a concentration-dependent way against human PC-3. Compound 1 demonstrated selectivity 26 
fold more potent than the positive control, doxorubicin, for PC-3 (prostrate) cell line based on 
GI
50
 values, causing cytostatic effect (TGI value) at a concentration fifteen times less than positive 
control. Moreover comparison of 50% lethal concentration (LC
50
 value) with positive control 
(doxorubicin) suggested that compound 1 was less toxic.
Keywords: Pterodon pubescens, leguminosae, furanoditerpenes, in vitro assay, prostate cell 
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Intoduction
Throughout history, natural products have afforded a rich 
source of compounds that have found many applications in 
the fields of medicine, pharmacy and biology. Within the 
sphere of cancer, a number of important new commercialized 
drugs have been obtained from natural sources, by structural 
modification of natural compounds, or by the synthesis of new 
compounds, designed following a natural compound as model. 
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Among the many compounds identified for cancer treatment 
Taxol, isolated from Taxus brevifolia, has proven to be an 
important chemotherapeutic agent.1 Medicinal plants still play 
an important role as source of new targets for drug discovery. 
The huge structural diversity of natural compounds and their 
bioactivity potential have meant that several products isolated 
from plants, marine flora and microorganisms can serve 
as “lead” compounds for improvement of their therapeutic 
potential by molecular modification.2,3
Pterodon genus compromises four species native 
to Brazil: P. abruptus Benth., P. apparucuri Pedersoli, 
P. pubescens Benth. (P. emarginatus Vog.) and P. 
polygalaeflorus Benth. Initially scientific studies of these 
plants were motivated by evidence that the seed’s oil had 
cercaricidal4 and anti-microbial activity.5
Pterodon pubescens Benth. (Leguminosae) known, as 
Sucupira Branca is widespread throughout Goiás, Minas 
Gerais and São Paulo states in Brazil. The seeds are 
commercially available in Brazilian medicinal flora market. 
Plant’s crude alcoholic extracts are used in folk medicine 
as anti-inflammatory, analgesic and anti-rheumatic 
preparations.5-7 
Phytochemical studies of Pterodon genus have revealed 
the presence of alkaloids, isoflavones and diterpenes. Furan-
diterpenes were identified and isolated from Pterodon 
fruits.8-11 Some authors have suggested that furan-diterpenes 
possessing vouacapan skeleton are involved with anti-
inflammatory properties of Pterodon pubescens seeds´ 
oil.5,12,13 Diterpenes 6α-hydroxyvouacapan-7β-17β-lactone 
and 6α, 7β-dihydroxyvouacapan-17β-oate methyl ester, 
present in P. emarginatus and P. polygalaeflorus seeds, 
respectively, were previously found to be associated with 
anti-inflammatory activity of these species.12 Another 
compound, acid 6,7-dihydroxyvouacapan-17β-oic, was 
suggested to be one of the possible compounds involved 
with anti-inflammatory activity, since this compound 
was identified in the active fraction that exhibited anti-
edematogenic activity when tested in carrageenin-induced 
paw edema or in Croton oil-induced ear edema assays.13 
Evidence of biogenic amines involved with 
antinociceptive effect of a vouacapans extracted from 
P. polygalaeflorus Benth was studied by Duarte et al.14 
suggested that the pharmacological activity was triggered 
by catecholaminergic system. 
Coelho et al.15 studied Pterodon seed extract’s 
antinociceptive activity suggesting that both peripheral and 
central inhibitory mechanisms are involved.
In the present study we report the isolation by activity-
guided fractionation, identification and in vitro anticancer 
activities of vouacapans from Pterodon pubescens Benth 
that are herein reported for the first time.
Results and Discussion
Compounds  6α , 7β -d iace toxyvouacapan  2 , 
7β-diacetoxyvouacapan 3,  6α,7β-dihydroxyvouacapan-
17β-oate methyl ester 4, and 6α,7β-dihydroxyvouacapan-
17β-methylene-ol 5 (Figure 1) were identified based on 
comparison of experimental 1H and 13C-NMR with reported 
spectral data.9,10,16,17 









by HREI-MS (observed 
M+. = 360.23556, required M+. = 360.23010), which 
indicated seven insaturation sites. Infrared absorptions 
at 3449 (OH) and 1713 (C=O) cm-1 provided evidences 
for hydroxyl and carbonyl functionalities. The 1H-NMR 
spectral data (Table 1) showed a signal at d
H
 3.48 (1H, 
dd, J 9.7; 9.3 Hz, H-7) that presented correlations 
with hydrogens H-8 (d
H
 1.88) and H-6 (d
H
 5.2) in H-H 
COSY experiment. This signal at d
H
 3.48 was attributed 
to a proton geminal to the hydroxyl group at C-7. 
Signal at d
H
 5.2 (1H, dd, J 11.7; 9.3Hz) was attributed 
hydrogen H-6, which was confirmed by correlations 
with hydrogens H-5 (d
H
 1.3) and H-7 (d
H
 3.48) in H-H 
COSY experiment. The coupling constant of hydrogens 
H-6 and H-7 was observed as 9.3 Hz indicating a trans-
diaxial relationship. When compound 1 was acetylated 
with excess acetic anhydride /pyridine, this compound 
showed identical 1H and 13C-NMR spectral data to 
compound 6α,7β-diacetoxyvouacapane 29 (HREI-MS 
402.2630), suggesting that compound 1 has the same 
relative configuration to 6α,7β-diacetoxyvouacapane 2 
Figure 1. Chemical structures of vouacapans 1, 2, 3, 4 and 5 isolated from 
Pterodon pubescens Benth. seeds.
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with a hydroxy group attached β to C-7 whereas the 
acetyl group positioned α at C-6 (Table 1).
The activity-guided fractionation of methylene chloride 
soluble fraction was monitored by in vitro anticancer 
activity assay in UACC-62 (melanoma), MCF-7 (breast), 
NCI-H460 (lung, non-small cells), OVCAR-3 (ovarian), 
PC-3 (prostate), HT-29 (colon), 786-0 (renal), K562 
(leukemia) and NCI-ADR/RES (ovarian expressing 
phenotype multiple drugs resistance) cancer cell lines. 
A 48 h SRB (Sulforhodamine B) cell viability assay was 
performed to determine growth inhibition and cytotoxic 
properties of fractions and compounds. Cells were treated 
with at least four different concentrations levels (0.25 
to 250 µg mL-1) with determination of three endpoints, 
concentration inhibiting the growth of 50% of the cells 
(GI50), concentration for total growth inhibition (TGI) and 
concentration needed to kill 50% of the cells (Table 2).18 






A mean graph for compounds 1-5 corroborated the 
selectivity of compounds 1, 4 and 5 for PC-3 human 
prostate cancer cell lines (Figure 2). The mean graph 
was developed by NCI emphasize differential effects of 
test compounds on various human tumor cell lines. This 
graph is generated from a set of GI
50
, TGI, or LC
50
 values. 
Positive values project to the right of the vertical line and 
represent cellular sensitivities to the test agent that exceed 
the mean. Negative values project to the left and represent 
cell line sensitivities to the test agent that are less than 
the average value.19  Based on the three graphics, PC-3 
cell line was high sensible to compounds 1, 4 and 5 . The 
interesting thing to notice is that compound 1 was more 
potent than 4 and 5 to inhibit cellular growth in 50% (GI
50
, 
Figure 2A), whereas compounds 1 and 5 showed almost 
same potency in causing cytostatic (TGI, Figure 2B). On 
the other hand, when cytotoxicity parameter (LC
50
, Figure 
2C) was evaluated, compound 5 was more toxic whereas 
1 and 4 were similarly toxics to PC-3 cell line. This high 
selectivity to PC-3 cell line suggests that furanoditerpenes 
1, 4 and 5 may share a similar action mechanism, probably 
evolving androgenic receptors.
Compound 4 was able to reduce in 50% cellular growth 
of MCF-7 and NCI-H460 cell lines and also presented 
activity against NCI/ADR-RES cell line measured by all 
three parameters.  
Compound 1 demonstrated selectivity 26 fold more 
potent than the positive control (doxorubicin) for PC-3 
(prostrate) cell line based on GI
50
 values, causing cytostatic 
effect (TGI value) at a concentration fifteen times inferior 
than positive control (doxorubicin). Moreover comparison 
Table 1. 1H and 13C NMR (11 Tesla, CDCl
3
/TMS) data for diterpene 1a










C-4 Co 33.1 -
C-5 CH 54.6 1.3 (d, J 11.7 Hz) 5.2
C-6 CH 76.4 5.2 (dd, J 11.7; 9.3Hz) 3.48; 1.3
C-7 CH 75.8 3.48 (dd, J 9.7; 9.3 Hz) 5.2; 1.88
C-8 CH 43.2 1.88 (td, J 9.7, 5.1 Hz) 3.48;3.13;1.92
C-9 CH 43.3 1.92 (ddd, J 12.3; 10.5; 5.1 Hz) 1.88; 0.95
C-10 Co 38.6 -
C-11 CH
2
22.6 0.95 (dd, J 12.3 Hz); 2.15 (dd, J 10.5 Hz) 1.92
C-12 Co 148.7 -
C-13 Co 121.7 -
C-14 CH 27.4 3.13 (d, J 5.1 Hz) 1.88
C-15 CH 109.6 6.21 (d, J 3.5 Hz) 7.25













aChemical shifts are in d (ppm).
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of 50% lethal concentration (LC
50
 value) with positive 
control (doxorubicin) demonstrated compound 1 to be 
less toxic.
Cytotoxicity in normal cell lines of compounds 1, 4, 
5 were evaluated against 3T3 cell line (mouse embryonic 
fibroblasts) assessing mitochondrial functions by MTT 
reduction with succinate dehydrogenase in order to 
obtain cell viability. Compound 1 (IC
50
 = 34.33 µg mL-1) 
demonstrated to be slightly less cytotoxic than compounds 
4 (IC
50
 = 22.83 µg mL-1) and 5 (IC
50
 = 23.55 µg mL-1). All 
these values were higher than almost all GI
50
 and TGI 
obtained for promissory compounds.
Cyproterone, a steroid formed by the mevalonate 
pathway is a known drug used as anti-androgen for prostrate 
cancer treatment.20 Cyproterone is a steroidal antiandrogen 
agent that inhibits the action of adrenal and testicular 
androgens on prostate cells, seminal vesicles, testes, and 
the vas deferens. Additionally causes a centrally mediated 
reduction in testicular secretion of androgens. This drug is 
indicated for treatment of prostate cancer, androgen induced 
disorders of the skin (acne, seborrhoea, hirsutism, alopecia), 
precocious puberty and sexual disorders in men.21,22
Male rats treated during two weeks with 100 and 
300 mg kg-1 doses of Pterodon pubescens dichloromethane 
crude extract decreased body weight gain by 57 and 75% 
respectively.23 That difference in body weight gain may 
have a relationship with antiandrogen activity of vouacapan 
type compounds found in the crude dichloromethane 
Table 2. Cytotoxic activity of compounds 1, 2, 3, 4 and 5
Cell lines 1 2 3 4 5 Doxorrubicin
UACC-62 GI
50
27.8 71.95 >250 12.7 6.23 0.02
TGI 64.47 >250 >250 39.58 118.3 0.19
LC
50
198.3 >250 >250 241.9 250 1.36
MCF-7 GI
50
69.7 148.1 212.6 3.2 5.18 0.20
TGI 172.88 >250 >250 20.97 105.3 2.69
LC
50
179.6 >250 >250 185.3 250 40.40
NCI-ADR/RES GI
50
30.5 >250 >250 3.3 3.02 0.09
TGI 96.72 >250 >250 11.56 21.43 5.31
LC
50
230.1 >250 >250 23.47 223.2 36.23
786-0 GI
50
28.5 86.16 196.6 5.2 2.86 0.03
TGI 59.30 >250 >250 24.29 14.41 0.26
LC
50
173.8 >250 >250 32.85 30.85 12.92
NCI-H460 GI
50
3.50 122.3 21.43 2.0 2.98 0.02
TGI 48.34 >250 >250 47.08 77.48 0.11
LC
50
228.8 >250 >250 250 250 2.14
PC-3 GI
50
0.0053 0.006 0.50 0.37 0.0085 0.14
TGI 0.38 >250 >250 0.27 0.17 4.53
LC
50
28.02 >250 214.4 15.80 4.85 5.90
Ovcar-03 GI
50
29.3 >250 >250 13.05 3.14 0.20
TGI 87.52 >250 >250 49.66 24.02 12.91
LC
50
243.4 >250 >250 240.0 178.6 250
HT-29 GI
50
60.9 >250 >250 10.8 19.04 0.25
TGI 200.7 >250 >250 37.97 35.83 2.26
LC
50
248.7 >250 >250 245.9 218.3 37.59
K562 GI
50
27.7 >250 132.8 4.1 3.37 0.22
TGI 80.97 >250 >250 26.29 36.16 2.02
LC
50
232.1 >250 >250 213.1 250 25.82
UACC-62 (melanoma), MCF-7 (breast), NCI-H460 (lung non-small cells), OVCAR-3 (ovarian), PC-3 (prostate), HT29 (colon), 786-0 (renal), K562 
(leukemia) and NCI-ADR/RES (ovarian expressing phenotype multiple drugs resistance). GI
50
: concentration (µg mL-1) inhibiting the growth of 50% of 
the cells; TGI: concentration (µg mL-1) total growth inhibition; LC
50
: concentration (µg mL-1) need to kill 50% of the cells.18
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extract. Decrease of mean final body weight was also 
observed with cyproterone after 15 days treatment.24 This 
data corroborates with the hypothesis that vouacapan type 
compounds interact with testosterone receptors. Further 
animal studies shall evaluate these findings.
Considering that compounds 1, 4 and 5, furan-
diterpenoid, also originates from the mevalonate biosynthetic 
pathway,20 PC-3 human tumor cell line inhibition observed 
might arise by similar pharmacological mechanism such as 
Cyproterone. Therefore compounds 1, 4, 5 are interesting 
pharmacophores capable of providing new insights to the 
understanding of agonist versus antagonist properties of 




IR spectra: JASCO-FT/IR-410 spectrometer. 1H, 
13C NMR and 2D experiments: Varian Inova-500 
spectrometer (11 Tesla). Chemical shifts were recorded in 
CDCl
3
 solutions and quoted relative to TMS (d 0.0, 1H NMR) 
and CHCl
3 
(d 77.0, 13C NMR). High-resolution electron 
ionization mass spectroscopy (HREIMS) was recorded 
on a VG-AutoSpec High Resolution Mass Spectrometer 
(70 eV) using direct probe. Column chromatography (CC): 
silica gel (0.063 × 0.200 mm, Merck). TLC (thin layer 
chromatography): precoated plates (775554 Merck), UV 
detection and anisaldehyde solution. 
Plant material
P. pubescens Benth. seeds were collected in Pedregulho 
(SP) and São Carlos (SP) cities, in march 2004. Prof. Dr. 
Jorge Yoshio Tamashiro from IB-UNICAMP (Department 
of Botany) identified the plant species. A voucher specimen 
was deposited at Universidade Estadual de Campinas 
(UEC) Herbarium, under numbers 1398 and 1402.
Figure 2. Patterns of differential cytotoxicity toward human tumor cell 
lines. A mean graph for compounds 1, 4 and 5 is shown. The midline 
of each portion represents the mean for GI
50
 (A), TGI (B) and LC
50
 
(C) endpoint, calculated across nine cell lines: UACC-62 (melanoma), 
MCF-7 (breast), NCI-ADR/RES (ovarian expressing phenotype multiple 
drugs resistance), 786-0 (renal), NCI-H460 (lung, non-small cells), PC-3 
(prostate), OVCAR-3 (ovarian), HT29 (colon), and K562 (leukemia). This 
mean value is then subtracted from the value for each individual cell line 
and plotted. Cell lines more sensitive are visualized as bars deflecting 
to the right, whereas more resistant cell lines have bars extending to the 
left of the mean.19
Figure 3. Cell viability test with compounds 1, 4, and, 5 on 3T3 cell lines 
(mouse fibroblast) after 48 hours exposure.
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Preparation of plant extract (EB) and fraction 
purification
Freeze-dried seeds (100g) were grinded prior to use 
on a Stephen mill (model UM 40 ) and extracted with 
dichloromethane three times during two hour periods, with 
5:1 solvent/plant ratio, at room temperature. The extract 




 filtered and concentrated 
under vacuum (Buchi RE 120), with 32% yield of crude 
seed oil extract (EB). 
This crude oil (18.2 g) was purified on pre-column 
chromatography using silica gel (Merck 7734) (5 × 60 cm) 
with hexane [FR1] (0-450 mL); hexane/ethyl acetate 
(95:5), [FR2] (500-900 mL); hexane/ethyl acetate 1(80:20) 
[FR3-4] (1000 x 1350 mL); hexane/ethyl acetate (60:40) 
(1400 x 1800 mL) [FR5-6]; hexane/ethyl acetate (40:60) 
(1900 x 2300 mL) [FR7]; rest flushed with methanol. 
The resulting fractions were monitored by thin layer 
chromatography (TLC), exposed with anysaldehyde 
reagent (50 mL acetic acid, 0.5 mL sulfuric acid and 0.5 mL 
anysaldehyde) followed by heating at 110 oC. According 
to TLC profile the fractions were group and submitted 
to biological assay. The in vitro anticancer model on 
nine human cell lines determined the fractions that were 
further purified. Among the fractions isolated by column 
chromatography, Fraction 7 presented the best anticancer 
in vitro activity (data not shown). 
Fraction 7 (10 g) was successively chromatographed 
by CC on silica-gel (70-230 mesh) (5 × 60 cm) and eluted 
with hexane/dichloromethane (7:3) (900-1800 mL) yielded 





(6:4) (1900-2600 mL) yielded 2 (990 mg, 9.9% yield), R
f
 
2 0.56;  hexane/dichloromethane (2:8) (2650-3100 mL) 
yielded 1 (963 mg, 9.63% yield), R
f 
1 0.29; (3350-4100 
mL) yielded 4 (1.2 g, 12% yield) R
f 










c 0.0094); FTIR ν
max
/cm-1: 3449, 1713; 1H and 13C NMR 
(11 Tesla, CDCl
3
/TMS): see Table 1.
6α,7b-diacetoxyvouacapan (2)
White crystal; mp 167.3-168.0 ºC; FTIR, 1H and 13C 
NMR data are in agreement with those reported in the 
literature.9,10,16,17
7b-acetoxyvouacapan (3)
White crystal; mp 125.6-127.2 ºC; FTIR, 1H and 13C 
NMR data are in agreement with those reported in the 
literature.9,10,16,17
6a,7b-dihydroxyvouacapan-17b-oate methyl ester (4)
Colorless oil; FTIR, 1H and 13C NMR data are in 
agreement with those reported in the literature.9,10,16,17
6a,7b-dihydroxyvouacapan-17b-methylene-ol (5)
Colorless oil; FTIR, 1H and 13C NMR data are in 
agreement with those reported in the literature.9,10,16,17
Chromatographic analysis
The GC/MS analysis were carried out using a HP-
6890/5975 system equipped with a J&W Scientific 
DB-5 fused capillary column (25 m x 0.2 mm x 0.33 m). 
Temperature program: 60 °C (5 oC min-1)-300 °C (10 min), 
injector 250 °C, detector 300 °C. Helium was used as carrier 
gas (0.7 bar, 1 mL min-1). The MS were taken at 70 eV. 
Scanning speed was 0.84 scans s-1, from 40 to 550. Sample 
volume was 1 µL. Split: 1:40.
In vitro anticancer activity assay 
Human tumour cell lines UACC-62 (melanoma), MCF-
7 (breast), NCI-H460 (lung, non-small cells), OVCAR-03 
(ovarian), PC-3 (prostate), HT-29 (colon), 786-0 (renal), 
K562 (leukemia) and NCI-ADR/RES (ovarian expressing 
phenotype multiple drugs resistance) were kindly provided 
by National Cancer Institute (NCI). Stock cultures were 
grown in medium containing 5 mL RPMI 1640 (GIBCO 
BRL) supplemented with 5% fetal bovine serum. 
Gentamicine (50 µg mL-1) was added to experimental 
cultures. Cells in 96 well plates (100 µL cells well-1) were 
exposed to sample concentrations in DMSO/RPMI (0.25, 
2.5, 25 and 250 µg mL-1) at 37 °C, 5% of CO
2
 in air for 
48 h. Final DMSO concentration did not affect cell viability. 
Afterwards cells were fixed with 50% trichloroacetic acid 
and cell proliferation determined by spectrophotometric 
quantification (540 nm) of cellular protein content using 
sulforhodamine B assay. Using the concentration-response 
curve for each cell line, GI
50
 (concentration that produces 
50% growth inhibition), TGI (concentration that produces 
total growth inhibition or cytostatic effect) and LC
50
 
(concentration that produces −50% growth, a cytotoxicity 
parameter) were determined through non-linear regression 
analysis (Table 2) using software ORIGIN 7.5 (OriginLab 
Corporation).18
In vitro cytotoxicity assay
Cell line 3T3 (mouse embryonic fibroblasts) was grown 
in medium containing 5 mL DMEM (glucose 4.5g L-1, 
glutamine 4 mmol L-1) (LGC Biotecnologia) supplemented 
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with 10% fetal bovine serum. Gentamicine (50 µg mL-1) 
was added to experimental cultures. Cells in 96 well plates 
(100 µL cells well-1, 1 × 104 cell mL-1) were exposed to 
sample concentrations in DMSO/RPMI (0.25, 2.5, 25 and 
250 µg mL-1) at 37 °C, 5% of CO
2
 in air for 48 h before 
MTT assay to access cell viability.25 Cells not exposed to 
samples were used as control. Final DMSO concentration 
did not affect cell viability. IC
50
 (concentration reducing 
cell viability in 50%) was determined through non-linear 
regression analysis using software ORIGIN 7.5 (OriginLab 
Corporation).
Conclusions
Considering the data  presented herein the 
chemotherapeutic potential of compounds 1, 4 and 5 were 
determined as possible candidates of new agents with high 
selectivity for prostate cancer. Further in vivo studies and 
in vitro assays are needed to establish pharmacological 
mechanism, toxicity and production viability.
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Figure S1. NMR1H (300 MHz, CDCL
3
) spectrum of  6α-acetoxy,7β-hydroxy vouacapan, 1.
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Figure S2. NMR13C (75.45 MHz, CDCL
3
) spectrum of 6α-acetoxy,7β-hydroxy vouacapan, 1.
Figure S3. NMR1H x 1H (500 MHz) (CDCL
3
) spectrum by COSY sequence of 6α-acetoxy,7β- hydroxy vouacapan, 1.
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Figure S4. NMR1H (300 MHz) x NMR13C (75.45 MHz, CDCL
3
) spectrum by HSQC sequence of 6α-acetoxy,7β-hydroxy vouacapan, 1.
Figure S5. NMR1H (500 MHz) x NMR13C (125.7 MHz, CDCL
3
) spectrum by HMQC sequence of 6α-acetoxy,7β-hydroxy vouacapan, 1.
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Figure S6. IR spectrum (Bomem MB Serie Hartmann & Braun-Michelson) of 6α-acetoxy,7β-hydroxy-vouacapan, 1.
Figure S7.  NMR 13C (75.45 MHz, CDCL
3
) DEPT 135 and 90 spectrum  of 6α-acetoxy,7β-hydroxy vouacapan, 1.
Spindola et al. S5Vol. 00, No. 00, 2009
Figure S8. NMR1H (300 MHz, CDCL
3
) spectrum of 6α,7β-diacetoxyvouacapan, 2.
Figure S9. NMR13C (75.45 MHz, CDCL
3
) spectrum of 6α,7β-diacetoxyvouacapan, 2.
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Figure S10. NMR13C (75.45 MHz, CDCL
3
) DEPT 135 and 90 spectrum  of 6α,7β-diacetoxyvouacapan, 2.
Figure S11. NMR1H (500 MHz) x NMR13C (125.7 MHz, CDCL
3
) spectrum by HETCOR sequence of 6α,7β-diacetoxyvouacapan, 2.
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Figure S12. NMR1H x 1H (300 MHz) spectrum by COSY sequence of 6α,7β-diacetoxyvouacapan, 2.
Figure S13. IR spectrum (Bomem MB Serie Hartmann & Braun-Michelson) of 6α,7β-diacetoxyvouacapan, 2.
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Figure S14. NMR1H (300 MHz, CDCL
3
) spectrum of  7β-acetoxivouacapano, 3.
Figure S15. NMR13C (75.45 MHz, CDCL
3
) spectrum of  7β-acetoxivouacapano, 3.
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Figure S16. NMR13C (125.7 MHz, CDCL
3
) DEPT 135 and 90 spectrum  of  7β-acetoxivouacapano, 3.
Figure S17.  NMR1H (300 MHz) x NMR13C (75.45 MHz, CDCL
3
) spectrum by HETCOR sequence of 7β-acetoxivouacapano.
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Figure S18. NMR1H x 1H(300 MHz) spectrum by COSY sequence of 7β-acetoxivouacapano, 3.
Figure S19. IR spectrum (Bomem MB Serie Hartmann & Braun-Michelson) of 7β-acetoxivouacapano, 3.
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Figure S20. NMR1H (500 MHz, CDCL
3
) spectrum of compound 4.
Figure S21. NMR13C (125,7 MHz, CDCL
3
) spectrum of compound 4.
